GCL
EUCRW

Glazer Capital LLC’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Glazer Capital LLC’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,584
Closed – – 613
2022
Q3 		$0 Hold
11,584
– – ﹤0.01% 755
2022
Q2 		$0 Sell
11,584
-8,500
-42% -$1.37K ﹤0.01% 798
2022
Q1 		$4K Sell
20,084
-5,000
-20% -$2.03K ﹤0.01% 547
2021
Q4 		$15K Buy
+25,084
New +$18.5K ﹤0.01% 787

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Glazer Capital LLC's EUCRW Position: Q4 2022 in Review

Glazer Capital LLC sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q4 2022, closing a stake of 11,584 shares.

Glazer Capital LLC first reported a position in EUCRW in Q4 2021 and held it in 4 quarters. The position peaked at $15K in Q4 2021. 25 funds tracked by Wall St. Rank hold EUCRW as of Q4 2022.

  • Glazer Capital LLC reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q4 2022 after selling out during the quarter.
  • Glazer Capital LLC sold 11,584 Eucrates Biomedical Acquisition Corp. Warrant shares in Q4 2022.
  • Glazer Capital LLC first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q4 2021 and held it in 4 quarters.
  • Glazer Capital LLC's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $15K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q4 2022.

Based on Glazer Capital LLC's 13F filing for Q4 2022, filed 14 Feb 2023.